

09/980370

JC10 Rec'd PCT/PTO 28 NOV 2001  
PATENT  
Docket No. 229752001500

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

I hereby certify that this paper or fee is being deposited on November 28, 2001 with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 as Express Mail Label No. EL779891711US and is addressed to: U.S. Patent and Trademark Office, Box Patent Application, P.O. Box 2327, Arlington, VA 22202

  
Michael Boyd

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Charles Andrew COLLYER, et al.

Serial No.: To be assigned

Int'l Application No.: PCT/AU00/00599

Int'l Filing Date: May 26, 2000

For: A METHOD OF PROPHYLAXIS AND  
TREATMENT AND AGENTS USEFUL FOR  
SAME

Examiner: To be assigned

Group Art Unit: To be assigned

PRE AMENDOT/A  
AJ  
P#9  
9-20-02

**PRELIMINARY AMENDMENT**

United States Patent and Trademark Office  
Box PCT  
P.O. Box 2327  
Arlington, VA 20231

Dear Sir:

The above-referenced application is being filed herewith under 35 U.S.C. § 371.

Please enter the following preliminary amendment in the above referenced application.

## AMENDMENTS

### In the Specification:

On page 1 following the PCT cover page, after the Title of the invention, after line 2, please insert the following paragraph:

### **CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is the U.S. National Phase of PCT International Application No. PCT/AU00/00599, filed May 26, 2000, which claims priority to Australian Provisional Patent Application No. PQ 0652, filed May 28, 1999, the disclosures of each of which are incorporated herein by reference in their entirety.

### In the Claims:

Please amend claims 3, 6-7 and 17 as follows.

3. (Amended) A method according to claim 1 wherein the biological environment is a mammal or reptile or insect or bird or species of fish.

6. (Amended) A method according to any one of Claims 1 to 4 wherein the HA2-containing molecule is a gingipain, an hagA gene product or a TonB-dependent protein such as but not limited to Tla protein or a homologue thereof.

7. (Amended) A method according to Claim 1 wherein the porphyrin moiety is a heme.

17. (Amended) A therapeutic composition comprising an agent according to Claim 12 or 13 and one or more pharmaceutically acceptable carriers and/or diluents.

Please add new claims 18-20 as follows: